Navigation Links
Tianyin Pharmaceutical Co., Inc. Authorizes $3.0 Million Stock Repurchase Program
Date:10/28/2008

CHENGDU, China, Oct. 28 /Xinhua-PRNewswire-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc., (Amex: TPI), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that the Company's board of directors has approved a $3 million stock repurchase program.

On October 27, 2008, the Board of Directors authorized the Company to repurchase up to $3.0 million of its common stock through January 2009. The amount and timing of specific repurchases are subject to market conditions, applicable legal requirements and other factors deemed appropriate by the Company's CEO and President. Repurchases may be in open-market transactions or through privately negotiated transactions, and the repurchase program may be expanded by the Board of Directors in the future. The Company has approximately 15.5 million shares of common stock outstanding and approximately 2.5 million shares are in the public float as of today. Any shares repurchased by the Company in this program will be retired to the treasury while reducing the number of outstanding shares of its common stock.

"After careful consideration and evaluating a number of suitable investment opportunities, we believe an investment in our Company has the potential to yield a significant return for our shareholders," stated Dr. Jiang, Chairman and CEO of Tianyin. "We currently maintain a strong balance sheet, with approximately $12.1 million in net cash and equivalents as of June 30, 2008, and are also cash flow positive from operations. Taking this buyback into consideration, we will have maintained a sufficient cash balance to complete the new solid dosage production plant without the need for raising any additional capital," Dr. Jiang
'/>"/>

SOURCE Tianyin Pharmaceutical, Co., Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Viscorp, Inc. Announces Name Change to Tianyin Pharmaceutical Co Inc. and Begins Trading Under the Ticker OTC BB: TYNP
2. Tianyin Pharmaceutical to Present at Roth Third Annual China Discovery Tour in Beijing on May 20, 2008 at 12:40 p.m. Beijing Time
3. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2008 Third Quarter Earnings Conference Call on Thursday, May 15, 2008 at 9:00 a.m. EDT
4. Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results
5. Tianyin Pharmaceutical Signs Over 60 New Distribution Agreements with 15 Regional Distributors
6. Tianyin Pharmaceutical Co., Inc. Completes Production for Earthquake
7. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Simvastatin Tablets
8. Tianyin Pharmaceutical Co., Inc. Announces Trading Symbol Error and Correction
9. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Laonian Kechuan Tablets
10. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
11. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... August 29, 2014 Evolutions Medical & ... in the Santa Barbara News-Press Readers’ Choice 2014 poll. ... Readers’ Choice poll as Best Medical Spa. The 2014 ... the following about Evolutions Medical Spa recognition: , “Not ... is recognized as a top-notch, cutting-edge medical spa as ...
(Date:8/29/2014)... August 29, 2014 ReputationChief.Com, a well-established ... named ‘Remove Bad Reviews’. This service has been launched ... account of negative reviews against them. , In order ... to deliver the committed results to its clients, ReputationChief.Com ... the world of internet marketing. , As per the ...
(Date:8/29/2014)... Graduate College of Social Work is the recipient of a ... the National Institute of Drug Abuse (NIDA) at the National ... health consequences of heroin use. Additionally, the grant provides resources ... , Heroin use has increased steadily since 2007 ... abuse to the cheaper and more available opioid. , ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 "After reading a ... don’t stand very often, I decided that there needed to ... during the day," said a concerned inventor from Sikestons, Mo. ... for long periods. It builds endurance and keeps the user ... health. Easy to use and producible in design variations, it's ...
(Date:8/29/2014)... hospitalized for a burn as a child experience higher than ... research at the University of Adelaide . , A ... by the University,s Centre for Traumatic Stress Studies. They ... of mental illness and 30% suffered depression at some stage ... journal Burns , also found that long-term ...
Breaking Medicine News(10 mins):Health News:Evolutions Named Best Medical Spa in Santa Barbara by Santa Barbara News Press 2Health News:Evolutions Named Best Medical Spa in Santa Barbara by Santa Barbara News Press 3Health News:ReputationChief.Com Announces a New Service ‘Remove Bad Reviews’ 2Health News:$1.25 million NIH grant to aid research on impact of heroin use 2Health News:Intervention needed for survivors of childhood burns 2
... you were at high risk of cancer because you carry ... A recent study at Fox Chase Cancer Center not only ... level and studied the parent perceptions of the impact of ... at the 2009 Annual Meeting of the American Society of ...
... study of targeted educational initiatives between the clinical staff ... their Partners program suggest that educational interventions by academic ... patients at community hospitals. The study, to be ... Society of Clinical Oncology, looked specifically at the number ...
... 14, 2009)Researchers at Fox Chase Cancer Center uncovered a ... tumor (GIST) patients respond to the targeted therapy imatinib ... that could be suppressed in order to make these ... PhD, a postdoctoral fellow in the laboratory of Andrew ...
... guide important treatment decisions, experts say , , THURSDAY, May ... at predicting colon cancer recurrence may help individualize treatment ... therapy choices, scientists say. , The Oncotype DX test ... more likely to have a recurrence and which were ...
... of new pharmaceutical products in the pipeline combined with ... for the rare disease community, a senior Food and ... hosted by the National Organization for Rare Disorders (NORD).The ... MD, director of the Center for Drug Evaluation and ...
... proteomic test as a predictor of overall survival benefit ... VeriStrat, a blood-based, proteomic test currently used for patients ... presented by Christine Chung, MD, Assistant Professor of Medicine ... at the 45th Annual Meeting of the American Society ...
Cached Medicine News:Health News:Should parents share the results of BRCA1/2 genetic testing with their children? 2Health News:Educational initiatives improve quality of care delivery 2Health News:Gene signature may predict patient response to therapy for gastrointestinal stromal tumors 2Health News:Gene Screen May Predict Colon Cancer's Return 2Health News:Gene Screen May Predict Colon Cancer's Return 3Health News:NORD Sponsors Rare Disease Summit 2Health News:May 14, 2009: Biodesix Announces VeriStrat(R) Data in Head and Neck Cancer to be Presented at ASCO 2Health News:May 14, 2009: Biodesix Announces VeriStrat(R) Data in Head and Neck Cancer to be Presented at ASCO 3
(Date:8/28/2014)... Takeda Pharmaceutical Company Limited ("Takeda") today announced ... of data from a 10-year epidemiology study to ... (U.S.) Food and Drug Administration (FDA), ... Ministry of Health, Labour, and Welfare (MHLW) / ... for pioglitazone containing medicines, including ACTOS (pioglitazone HCl). ...
(Date:8/28/2014)... , Aug. 28, 2014  In anticipation of the upcoming ... being made available for the first time. Industry Overview: ... offers a snapshot of San Diego,s ... Highlighting everything from the latest employment statistics to current venture ... San Diego such a vital part of ...
(Date:8/28/2014)... /PRNewswire-iReach/ -- Academy Leadership, an elite leadership training firm ... a case study highlighting one manager,s experience ... In September and October 2014, Academy Leadership affiliates are ... , Indianapolis , Salt Lake City , ... http://photos.prnewswire.com/prnh/20140828/140814 Leadership training for managers ...
Breaking Medicine Technology:Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 2Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 3Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 4Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 5Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 6New Infographic Published - Overview of Medtech & Life Sciences Industry in San Diego 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5
... , FRIMLEY, England, December 8 ... Measures of Treatment Effectiveness,in the Trial, in Patients With Newly-Diagnosed Disease(1) , ... Later Stages,of the Disease on nilotinib (300mg Twice-Daily and 400mg Twice-Daily) Than ... Well Tolerated; Only a Small Number of Patients,Discontinued Due to Adverse Events(1) ...
... Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical ... cancer, inflammation and autoimmune diseases, today announced data from ... patients with B-precursor acute lymphoblastic leukemia (ALL). The data ... Annual Meeting of the American Society of Hematology (ASH) ...
Cached Medicine Technology:Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 3Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 4
... (tTg) is a ubiquitous enzyme that ... transglutaminase is also the specific protein ... antibody immunofluorescence (EMA) tests (Bio-Rad catalog ... and,IgG serologic tests are highly sensitive ...
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
Medicine Products: